^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + AB-329 (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
Published date:
03/09/2023
Excerpt:
For all patients (n = 13), stable disease was achieved in 9 (69.2%), progressive disease in 3 (23.1%)...Based on the best overall response, the disease control rate (DCR) was 69.2% (95% CI 39–91)….Median PFS was 12.4 weeks (95% CI 6.9–36.6) and median OS was 41.9 weeks (95% CI 31.7–not evaluable) weeks (Table 4)....This phase 1 study demonstrated that DS-1205c was well-tolerated in patients with advanced EGFR-mutant NSCLC when administered in combination with osimertinib. No new safety/tolerability signals were identified.
DOI:
10.1007/s10637-023-01341-y
Trial ID:
